WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005014823) TARGETED CARRIER FUSIONS FOR DELIVERY OF CHEMOTHERAPEUTIC AGENTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/014823    International Application No.:    PCT/US2004/025376
Publication Date: 17.02.2005 International Filing Date: 05.08.2004
IPC:
A61K 47/48 (2006.01), C07K 14/36 (2006.01)
Applicants: WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; 614 North Walnut Street - 13th floor, P.O. Box 7365, Madison, WI 53707-7465 (US) (For All Designated States Except US).
SHEN, Ben [CN/US]; (US) (For US Only)
Inventors: SHEN, Ben; (US)
Agent: HIGHLANDER, Steven, L.; Fulbright & Jaworski, LLP, 600 Congress Avenue, Suite 2400, Austin, TX 78701 (US)
Priority Data:
60/492.508 05.08.2003 US
Title (EN) TARGETED CARRIER FUSIONS FOR DELIVERY OF CHEMOTHERAPEUTIC AGENTS
(FR) FUSIONS DE VECTEURS CIBLES POUR ADMINISTRER DES AGENTS CHIMIOTHERAPEUTIQUES
Abstract: front page image
(EN)The present invention provides for fusion proteins that act as targeted drug carriers. The proteins are derived from molecules that possess natural drug-binding capabilities that are further engineered to target specific cell types, and optionally to have altered/improved drug binding characteristics. These fusion proteins are useful in, for example, delivery of chemotherapeutic compounds to cancer cells.
(FR)L'invention concerne des protéines hybrides qui agissent en tant que vecteurs de médicaments cibles. Les protéines sont dérivées de molécules qui possèdent des possibilités naturelles de liaison du médicament, lesquelles sont de plus transformées en types de cellules spécifiques cibles, et elles présentent éventuellement des caractéristiques de liaison de médicaments transformées/améliorées. Lesdites protéines hybrides sont utilisées dans l'administration, par exemple, de composés thérapeutiques à des cellules cancéreuses.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)